An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Trial Profile

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 12 Dec 2017 Preliminary results (data cut off: Jul 2017, n=19) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Nov 2017 According to a Kura Oncology media release, data from the study will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 25 Jun 2017 Preliminary results (n=18, data cut off: 2/15/2017) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top